OTC IBUPROFEN MARKETERS AHP AND B-M LEAD INDEX AS MARKET CONTINUES SLIDE

Executive Summary

OTC IBUPROFEN MARKETERS AHP AND B-M LEAD INDEX AS MARKET CONTINUES SLIDE The stock market reacted to the good news of the ibuprofen OTC switch and the bad news everywhere else as only American Home Products (up 1 to 52) among the 52 Index stocks advanced more than fractionally. Just behind, among advancing stocks, was OTC ibuprofen competitor Bristol-Myers (up 3/4 to 44-1/2). Only seven other pharmaceutical/health care stocks on the Index made fractional gains, with two just breaking even. Hardest hit among Diversified stocks were Novo (off 5 to 43-1/4) an Forest (down 3 to 15). Pharmaceutical stocks declining the furthest were Syntex (down 3-3/4 to 39-1/4), Lilly (down 3-1/8 to 58), Upjohn (down 2-7/8 to 65), and two point losers Rorer (off to 28-3/8) and Abbott (to 40-1/8). Overall, 27 of 52 Index issues declined by a point or more. Chart omitted.